ERBB2 and breast carcinoma: Trastuzumab (Herceptin), a humanized monoclonal antibody against the extracellular domain of HER2 [3-5], has shown significant therapeutic benefit in the treatment of patients with HER2-overexpressing breast cancer [6-20].